Glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide (Wegovy, Ozempic) and liraglutide (Saxenda), have gained attention for their role in weight management and diabetes treatment. These medications work by regulating appetite, slowing digestion, and improving insulin sensitivity. While they have been widely used in adults, their use in adolescents is a growing area of research and debate.

In 2023, the American Academy of Pediatrics (AAP) released updated guidelines on the treatment of children and adolescents with overweight and obesity — the first major update in 15 years. These new recommendations have generated a great deal of discussion — especially among pediatricians, therapists, dietitians, and parents of children in larger bodies.